女性避孕市场－全球产业规模、份额、趋势、机会和预测（按避孕药物、设备、地区和竞争细分，2020-2030 年）

2024 年全球女性避孕市场价值为 150.1 亿美元，预计到 2030 年将以 6.24% 的复合年增长率强劲增长。该市场包括各种各样的产品和设备，旨在防止意外怀孕并支持女性的生殖自主权。避孕选择包括避孕药、植入物和贴片等荷尔蒙方法，以及屏障避孕法、子宫内避孕器 (IUD) 和紧急避孕药。该行业在计划生育、降低孕产妇死亡率和支持全球妇女健康方面发挥关键作用。人们对生殖健康的认识不断提高、医疗保健的可及性不断提高、政府的支持性倡议以及不断发展的社会规范正在推动需求。根据联合国人口基金会 2022 年的报告，全球每年发生近 1.21 亿例意外怀孕，凸显了对有效避孕解决方案的迫切需求。产品开发的创新和文化观念的转变继续加强全球市场扩张。

关键市场驱动因素

妇女赋权

主要市场挑战

有限的访问和意识

主要市场趋势

副作用较少的荷尔蒙避孕药

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：全球女性避孕市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 避孕药（口服避孕药、避孕针剂、外用避孕药、杀精剂）
  • 按装置分类（女用保险套、隔膜和帽子、阴道环、避孕海绵、皮下避孕植入物、子宫内避孕器 (IUCD)、其他）
  • 按地区
  • 按公司分类（2024）
• 产品市场图
  • 避孕药
  • 按设备
  • 按地区

第六章：北美女性避孕市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲女性避孕市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙

第八章：亚太女性避孕市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国

第九章：南美洲女性避孕市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第十章：中东与非洲女性避孕市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 近期发展
• 併购
• 产品发布

第十三章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 14 章：竞争格局

• Bayer AG
• Mayer Laboratories Inc
• Pfizer Inc
• Mylan Pharmaceuticals Inc
• Teva Pharmaceutical Industries Ltd
• Organon & Co.
• Agile Therapeutics Inc
• Lupin Pharmaceuticals Inc
• The Female Health Company
• FUJI LATEX CO.,LTD.

第 15 章：策略建议

第16章调查会社について・免责事项

The Global Female Contraceptive Market was valued at USD 15.01 billion in 2024 and is projected to witness strong growth with a CAGR of 6.24% through 2030F. This market includes a diverse range of products and devices designed to prevent unintended pregnancies and support reproductive autonomy for women. Contraceptive options include hormonal methods like pills, implants, and patches, as well as barrier methods, intrauterine devices (IUDs), and emergency contraceptives. The sector plays a key role in family planning, reducing maternal mortality, and supporting women's health globally. Growing awareness about reproductive health, increased healthcare accessibility, supportive government initiatives, and evolving social norms are propelling demand. According to the UNFPA's 2022 report, nearly 121 million unintended pregnancies occur globally each year, highlighting the critical need for effective contraceptive solutions. Innovation in product development and shifting cultural attitudes continue to strengthen market expansion worldwide.

Key Market Drivers

Women's Empowerment

Women's empowerment is a major catalyst for growth in the female contraceptive market, influencing healthcare decision-making and reproductive autonomy. Educated and informed women are better equipped to make decisions regarding contraception that align with their health needs and personal circumstances. Greater empowerment improves access to healthcare services, prompting more women to utilize family planning clinics and seek out reliable contraceptive options. As economic independence grows, women are increasingly able to afford and prioritize contraceptive products and services. This economic and social empowerment drives demand, encouraging pharmaceutical companies to innovate and expand contraceptive offerings to meet diverse needs across different populations.

Key Market Challenges

Limited Access and Awareness

Limited access to and awareness of contraceptive options remains a major barrier in the global female contraceptive market, particularly in underprivileged and rural areas. Many women face financial, cultural, or geographic constraints that prevent them from obtaining reliable contraceptives. A lack of education and knowledge about available methods also contributes to low adoption rates. Addressing this challenge requires coordinated efforts by governments, NGOs, and international health organizations to expand education campaigns and improve access to family planning services. By empowering women with accurate information and affordable options, these initiatives aim to reduce disparities and foster informed reproductive choices.

Key Market Trends

Hormonal Contraceptives with Reduced Side Effects

A significant trend shaping the female contraceptive market is the development of hormonal contraceptives designed to minimize side effects. Manufacturers are investing in research to produce solutions that effectively prevent pregnancy while reducing issues such as mood changes, weight gain, and reduced libido. These innovations aim to enhance the user experience, making hormonal contraceptives more appealing and acceptable to a broader population. As awareness of long-term reproductive health grows, demand for safer, user-friendly options is driving the evolution of new-generation hormonal contraceptives with improved tolerability and efficacy.

Key Market Players

• Bayer AG
• Mayer Laboratories Inc
• Pfizer Inc
• Mylan Pharmaceuticals Inc
• Teva Pharmaceutical Industries Ltd
• Organon & Co.
• Agile Therapeutics Inc
• Lupin Pharmaceuticals Inc
• The Female Health Company
• FUJI LATEX CO.LTD.

Report Scope:

In this report, the Global Female Contraceptive Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Female Contraceptive Market, By Contraceptive Drugs:

• Oral Contraceptives
• Contraceptive Injections
• Topical Contraceptives
• Spermicides

Female Contraceptive Market, By Device:

• Female Condoms
• Diaphragms and Caps
• Vaginal Rings
• Contraceptive Sponges
• Sub-dermal Contraceptive Implants
• Intra Uterine Contraceptive Devices (IUCDs)
• Others

Female Contraceptive Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Female Contraceptive Market.

Available Customizations:

Global Female Contraceptive market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Female Contraceptive Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Contraceptive Drugs (Oral Contraceptives, Contraceptive Injections, Topical Contraceptives, Spermicides)
  • 5.2.2. By Device (Female Condoms, Diaphragms and Caps, Vaginal Rings, Contraceptive Sponges, Sub-dermal Contraceptive Implants, Intra Uterine Contraceptive Devices (IUCDs), Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Product Market Map
  • 5.3.1. By Contraceptive Drugs
  • 5.3.2. By Device
  • 5.3.3. By Region

6. North America Female Contraceptive Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Contraceptive Drugs (Oral Contraceptives, Contraceptive Injections, Topical Contraceptives, Spermicides)
  • 6.2.2. By Device (Female Condoms, Diaphragms and Caps, Vaginal Rings, Contraceptive Sponges, Sub-dermal Contraceptive Implants, Intra Uterine Contraceptive Devices (IUCDs), Others)
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Female Contraceptive Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Contraceptive Drugs
      • 6.3.1.2.2. By Device
  • 6.3.2. Canada Female Contraceptive Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Contraceptive Drugs
      • 6.3.2.2.2. By Device
  • 6.3.3. Mexico Female Contraceptive Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Contraceptive Drugs
      • 6.3.3.2.2. By Device

7. Europe Female Contraceptive Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Contraceptive Drugs (Oral Contraceptives, Contraceptive Injections, Topical Contraceptives, Spermicides)
  • 7.2.2. By Device (Female Condoms, Diaphragms and Caps, Vaginal Rings, Contraceptive Sponges, Sub-dermal Contraceptive Implants, Intra Uterine Contraceptive Devices (IUCDs), Others)
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Female Contraceptive Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Contraceptive Drugs
      • 7.3.1.2.2. By Device
  • 7.3.2. United Kingdom Female Contraceptive Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Contraceptive Drugs
      • 7.3.2.2.2. By Device
  • 7.3.3. France Female Contraceptive Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Contraceptive Drugs
      • 7.3.3.2.2. By Device
  • 7.3.4. Italy Female Contraceptive Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Contraceptive Drugs
      • 7.3.4.2.2. By Device
  • 7.3.5. Spain Female Contraceptive Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Contraceptive Drugs
      • 7.3.5.2.2. By Device

8. Asia-Pacific Female Contraceptive Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Contraceptive Drugs (Oral Contraceptives, Contraceptive Injections, Topical Contraceptives, Spermicides)
  • 8.2.2. By Device (Female Condoms, Diaphragms and Caps, Vaginal Rings, Contraceptive Sponges, Sub-dermal Contraceptive Implants, Intra Uterine Contraceptive Devices (IUCDs), Others)
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Female Contraceptive Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Contraceptive Drugs
      • 8.3.1.2.2. By Device
  • 8.3.2. Japan Female Contraceptive Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Contraceptive Drugs
      • 8.3.2.2.2. By Device
  • 8.3.3. India Female Contraceptive Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Contraceptive Drugs
      • 8.3.3.2.2. By Device
  • 8.3.4. Australia Female Contraceptive Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Contraceptive Drugs
      • 8.3.4.2.2. By Device
  • 8.3.5. South Korea Female Contraceptive Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Contraceptive Drugs
      • 8.3.5.2.2. By Device

9. South America Female Contraceptive Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Contraceptive Drugs (Oral Contraceptives, Contraceptive Injections, Topical Contraceptives, Spermicides)
  • 9.2.2. By Device (Female Condoms, Diaphragms and Caps, Vaginal Rings, Contraceptive Sponges, Sub-dermal Contraceptive Implants, Intra Uterine Contraceptive Devices (IUCDs), Others)
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Female Contraceptive Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Contraceptive Drugs
      • 9.3.1.2.2. By Device
  • 9.3.2. Argentina Female Contraceptive Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Contraceptive Drugs
      • 9.3.2.2.2. By Device
  • 9.3.3. Colombia Female Contraceptive Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Contraceptive Drugs
      • 9.3.3.2.2. By Device

10. Middle East and Africa Female Contraceptive Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Contraceptive Drugs (Oral Contraceptives, Contraceptive Injections, Topical Contraceptives, Spermicides)
  • 10.2.2. By Device (Female Condoms, Diaphragms and Caps, Vaginal Rings, Contraceptive Sponges, Sub-dermal Contraceptive Implants, Intra Uterine Contraceptive Devices (IUCDs), Others)
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Female Contraceptive Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Contraceptive Drugs
      • 10.3.1.2.2. By Device
  • 10.3.2. Saudi Arabia Female Contraceptive Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Contraceptive Drugs
      • 10.3.2.2.2. By Device
  • 10.3.3. UAE Female Contraceptive Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Contraceptive Drugs
      • 10.3.3.2.2. By Device

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Bayer AG
  • 14.1.1. Business Overview
  • 14.1.2. Product Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Key Personnel
  • 14.1.6. SWOT Analysis
• 14.2. Mayer Laboratories Inc
• 14.3. Pfizer Inc
• 14.4. Mylan Pharmaceuticals Inc
• 14.5. Teva Pharmaceutical Industries Ltd
• 14.6. Organon & Co.
• 14.7. Agile Therapeutics Inc
• 14.8. Lupin Pharmaceuticals Inc
• 14.9. The Female Health Company
• 14.10. FUJI LATEX CO.,LTD.

15. Strategic Recommendations

16.About Us & Disclaimer